Wesana Health and MAPS have announced the receipt of a commercial viability analysis conducted by the Boston Consulting Group (BCG) which will bring the parties closer to conducting research on MDMA for the treatment of TBIs.
The Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Public Benefit Corporation (MAPS PBC) and data-driven life sciences company Wesana Health Holdings have announced the receipt of the BGC analysis indicating viability of a research pathway.
The analysis validated and will expedite the parties’ partnership talks in order to move forward in the definitive agreement to study the use of MDMA-assisted therapy to treat symptoms associated with TBIs.
MAPS executive director, Rick Doblin, Ph.D., commented: “This analysis brings us one step closer to partnering with Wesana to conduct research into the potential of MDMA-assisted therapy in the massively underserved TBI population.
“This market analysis makes the case even more compelling for our partnership.”
CEO of Wesana Health, Daniel Carcillo, added: “The receipt of favourable results in the MAPS-commissioned BCG report is a critical milestone in what will be the first-of-its-kind collaboration between MAPS and Wesana, facilitating our definitive agreement conversations regarding MDMA-assisted therapy for TBI symptoms.”
The agreement is expected to accelerate the parties’ research timelines and as well as provide additional support for further investigation, advocacy, education, and equitable access to MDMA-assisted therapy for TBI symptoms.
Carcillo concluded that: “With the overall reported cost of TBI in the range of ~$76.5bn annually in the US, we know the market is ready for a new solution.
“We remain committed to this important work and as we move toward our goal of MDMA-assisted therapy for TBI, we are thrilled to move forward with our efforts deliver meaningful help to victims, families, friends and communities whose lives have been impacted by TBI.”
[activecampaign form=52]
